Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Endocrinology

Life After Treatment: Monitoring and Wellness

At a Glance

Life after hyperprolactinemia treatment focuses on restoring hormone balance, recovering fertility, and monitoring long-term health. Regular check-ups are essential to track bone density, ensure the ongoing safety of medications like cabergoline, and manage anxiety surrounding routine MRI scans.

Successfully treating hyperprolactinemia is a major milestone, but it also begins a new phase of long-term health maintenance. For most patients, this “new normal” involves transitioning from active treatment to periodic surveillance to ensure hormone levels remain stable and complications are managed [1][2].

Restoring Your Biological Rhythm

One of the most rewarding aspects of treatment is the restoration of hormonal and reproductive health.

  • For Women: Normalizing prolactin with dopamine agonists is highly effective at restoring regular menstrual cycles and ovulation [3][4]. Most women see a return of their periods shortly after their prolactin levels reach the normal range [1].
  • For Men: Treatment often leads to improved sex drive (libido) and erectile function [5][6]. While the restoration of sperm quality can take longer, the normalization of hormones is the critical first step toward full reproductive health [7].

Family Planning and Unexpected Pregnancies

It is crucial to understand that ovulation can return before your first menstrual period. Therefore, women of childbearing age who do not wish to conceive should begin using contraception once treatment begins [3].

If you do become pregnant while taking a dopamine agonist, contact your endocrinologist immediately. The standard medical protocol is typically to stop the medication as soon as pregnancy is confirmed, unless your doctor advises you to stay on it due to a large, rapidly growing tumor (macroadenoma) [3][1]. Do not adjust your medication without medical supervision.

Protecting Your Long-Term Bone Health

Because long-term high prolactin can “thin” your bones, monitoring your bone mineral density is essential even after your levels are normal.

  • The DXA Scan: This is the gold-standard test used to check for osteopenia (mild bone loss) or osteoporosis (more severe bone loss) [8][9].
  • Maintenance: Once your hormones are balanced, your bone density often stabilizes or improves. However, your doctor may still recommend periodic DXA scans to ensure your skeleton remains strong [10][11].

Long-Term Safety of Cabergoline

If you are taking cabergoline long-term, your doctor will monitor for a rare side effect called valvulopathy (heart valve thickening) [12][13].

  • The Safety Range: Research shows that cabergoline is generally very safe at the doses used for pituitary issues, especially until you reach a cumulative dose of 300 mg (the total amount you have taken over your entire life) [14][15].
  • Monitoring: Routine heart ultrasounds (echocardiograms) are usually only necessary for patients taking high weekly doses (2 mg or more) or those who develop a new heart murmur [16][17].

Managing “Scanxiety” and the Emotional Burden

Living with a chronic condition and requiring regular MRIs can lead to scanxiety—the intense stress and anxiety felt before a scan and while waiting for results [18][19].

  • The Impact: This distress is a common and valid part of the patient experience. It can disrupt your daily life and make it feel difficult to “move on” from your diagnosis [20][21].
  • Coping Strategies:
    • Ask for Speed: Request that your results be shared as soon as they are ready to minimize the “waiting window” [20].
    • Stay Informed: Patients who receive clear information about their scans often feel less anxious than those who feel “in the dark” [22][23].
    • Focus on the Present: While it is natural to worry about the future, focusing on your current health and symptoms can help ground you [24][25].

Remember, the goal of monitoring is not just to check for a tumor, but to ensure you are living a full, healthy, and empowered life [6].

Back to Home.

Common questions in this guide

When will my fertility and menstrual cycle return after hyperprolactinemia treatment?
Normalizing prolactin levels with dopamine agonists is highly effective at restoring regular menstrual cycles and ovulation. Most women see a return of their periods shortly after their prolactin reaches the normal range. Because ovulation can return before your first period, it is important to use contraception if you are not trying to conceive.
Is it safe to take cabergoline long-term for high prolactin?
Cabergoline is generally very safe at the standard doses used for pituitary conditions. Your doctor will track your lifetime cumulative dose to prevent rare side effects like heart valve thickening. Routine heart ultrasounds are usually only needed if you take high weekly doses or develop a new heart murmur.
Why do I need a DXA scan after my prolactin levels are normal?
Long-term high prolactin levels can thin your bones and lead to conditions like osteopenia or osteoporosis. Even after your hormone levels normalize, your doctor may recommend periodic DXA scans to ensure your bone density stabilizes and your skeleton remains strong.
What should I do if I get pregnant while taking a dopamine agonist?
If you become pregnant while on treatment for high prolactin, you should contact your endocrinologist immediately. The standard medical protocol is typically to stop the medication as soon as pregnancy is confirmed, but do not stop taking it without your doctor's supervision.
How can I manage anxiety before my routine MRI scans?
Experiencing scanxiety is a common and valid part of living with a chronic condition requiring regular imaging. You can help manage this stress by asking your doctor to share results as soon as they are ready, which minimizes your waiting time in the dark.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current dose of cabergoline, how close am I to the 300 mg cumulative dose limit, and do I need an echocardiogram?
  2. 2.When should we schedule my next DXA scan to confirm my bone density is improving now that my prolactin is normal?
  3. 3.Now that my levels are stable, what is a realistic timeline for my fertility or menstrual cycle to return to normal?
  4. 4.Is it possible to receive my MRI results through a patient portal as soon as they are available to minimize my waiting anxiety?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas.

    Auriemma RS, De Alcubierre D, Pirchio R, et al.

    Frontiers in endocrinology 2019; (10()):327 doi:10.3389/fendo.2019.00327.

    PMID: 31191454
  2. 2

    A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.

    Ceravolo R, Rossi C, Del Prete E, Bonuccelli U

    Expert opinion on drug safety 2016; (15(2)):181-98 doi:10.1517/14740338.2016.1130128.

    PMID: 26646536
  3. 3

    An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.

    O'Sullivan SM, Farrant MT, Ogilvie CM, et al.

    The Australian & New Zealand journal of obstetrics & gynaecology 2020; (60(3)):405-411 doi:10.1111/ajo.13070.

    PMID: 31583693
  4. 4

    Cabergoline monotherapy in polycystic ovary syndrome patients with elevated prolactin: a viable option?

    Sıgınır A, Bostan H, Saygılı ES, et al.

    Endocrine 2025; (89(2)):547-555 doi:10.1007/s12020-025-04279-8.

    PMID: 40399716
  5. 5

    [Current diagnosis and treatment of hyperprolactinemia].

    Melgar V, Espinosa E, Sosa E, et al.

    Revista medica del Instituto Mexicano del Seguro Social 2016; (54(1)):111-21.

    PMID: 26820213
  6. 6

    Common variants at 10p12.31, 10q21.1 and 13q12.13 are associated with sporadic pituitary adenoma.

    Ye Z, Li Z, Wang Y, et al.

    Nature genetics 2015; (47(7)):793-7 doi:10.1038/ng.3322.

    PMID: 26029870
  7. 7

    Study of Clinical Profile and Early Response to Dopamine Agonist Therapy in Patients of Hyperprolactinemia: Experience at a Tertiary Care Centre of Nepal.

    Nepal R, Bajracharya MR, Karki BB, et al.

    Indian journal of endocrinology and metabolism 2025; (29(6)):667-673 doi:10.4103/ijem.ijem_252_25.

    PMID: 41497301
  8. 8

    Characterization of bone disease in cystic fibrosis.

    Contreras-Bolívar V, Andreo-López MC, Muñoz-Torres M

    Medicina clinica 2025; (164(1)):23-29 doi:10.1016/j.medcli.2024.05.014.

    PMID: 39019666
  9. 9

    Assessing Bone Mineral Density Using Radiographs of the Hand: A Multicenter Validation.

    Burton H, Bodansky D, Silver N, et al.

    The Journal of hand surgery 2023; (48(12)):1210-1216 doi:10.1016/j.jhsa.2023.08.009.

    PMID: 37737801
  10. 10

    Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health.

    Andereggen L, Frey J, Andres RH, et al.

    World neurosurgery 2017; (97()):595-602 doi:10.1016/j.wneu.2016.10.059.

    PMID: 27773859
  11. 11

    Artifacts affecting dual-energy X-ray absorptiometry and bone mineral density measurements: a case report and review of the literature.

    White K, Shakir MKM, Nguyen C, Hoang TD

    Journal of medical case reports 2025; (19(1)):290 doi:10.1186/s13256-025-05353-5.

    PMID: 40544295
  12. 12

    Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.

    Tran T, Brophy JM, Suissa S, Renoux C

    CNS drugs 2015; (29(12)):985-98 doi:10.1007/s40263-015-0293-4.

    PMID: 26585874
  13. 13

    Severe Iatrogenic Tricuspid Regurgitation.

    Amaral Pinto I, Macedo D, Rei Neto R

    Cureus 2026; (18(5)):e108827 doi:10.7759/cureus.108827.

    PMID: 42291968
  14. 14

    Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.

    Khare S, Lila AR, Patil R, et al.

    Indian journal of endocrinology and metabolism 2017; (21(1)):154-159 doi:10.4103/2230-8210.196010.

    PMID: 28217516
  15. 15

    Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.

    Budayr A, Tan TC, Lo JC, et al.

    BMC endocrine disorders 2020; (20(1)):25 doi:10.1186/s12902-020-0507-8.

    PMID: 32075620
  16. 16

    The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening.

    Caputo C, Prior D, Inder WJ

    Journal of the Endocrine Society 2018; (2(8)):965-969 doi:10.1210/js.2018-00139.

    PMID: 30083627
  17. 17

    Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review.

    Gamble D, Fairley R, Harvey R, et al.

    Therapeutic advances in drug safety 2017; (8(7)):215-229 doi:10.1177/2042098617703647.

    PMID: 28845230
  18. 18

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  19. 19

    Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

    Bui KT, Kiely BE, Dhillon HM, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

    PMID: 34333717
  20. 20

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  21. 21

    Beyond remission: The unspoken reality of cancer survivorship.

    Marcon LR

    Explore (New York, N.Y.) 2026; (22(4)):103424 doi:10.1016/j.explore.2026.103424.

    PMID: 42070365
  22. 22

    MRI-Related Claustrophobia: Patient-Reported Experience and Associated Factors in a Makkah Region Cohort.

    Aldahery ST, Bushara LA, Alasami RA, et al.

    Tomography (Ann Arbor, Mich.) 2026; (12(6)) doi:10.3390/tomography12060077.

    PMID: 42347132
  23. 23

    The experience of patients participating in a small randomised control trial that explored two different interventions to reduce anxiety prior to an MRI scan.

    Tugwell-Allsup J, Pritchard AW

    Radiography (London, England : 1995) 2018; (24(2)):130-136 doi:10.1016/j.radi.2017.11.001.

    PMID: 29605109
  24. 24

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  25. 25

    Scanxiety Conversations on Twitter: Observational Study.

    Bui KT, Li Z, Dhillon HM, et al.

    JMIR cancer 2023; (9()):e43609 doi:10.2196/43609.

    PMID: 37074770

This page provides general information about life after hyperprolactinemia treatment and monitoring. It is not intended to replace professional medical advice. Always consult your endocrinologist regarding your specific medications, fertility plans, and scan results.

Get notified when new evidence is published on acquired hyperprolactinemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.